Clinical Oncology Next Generation Sequencing (NGS) Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1066489
  • May 2021
  • Biotechnology
  • 128 Pages
The Clinical Oncology Next Generation Sequencing (NGS) market research report provides an in-depth analysis of the currents trends, latest developments, scenario, market size, various drivers, restraints, and major players along with their profile details. Research report offers the historic data for year 2018 and 2019 and also provides the forecast data from year 2020 to 2028 which is based on revenue (USD Million). With the help of all these information research report helps the market participants to improve market positions. With the help of all these insights Clinical Oncology Next Generation Sequencing (NGS) market research report recommends a business strategy for present market participants to strengthen their position in the market.
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2020
Forecast Period Covered 2020 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Companies Covered Agilent Technologies, Inc., Caris Life Sciences, F. Hoffmann-La Roche Ltd, FOUNDATION MEDICINE, INC., Illumina, Inc., Myriad Genetics, Inc., Oxford Nanopore Technologies, Paradigm Diagnostics, Inc., QIAGEN, Thermo Fisher Scientific Inc.
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

COVID-19 Impact Analysis
The analysis of covid-19 is based on the impact of the current pandemic situation on market scenarios. This includes impact of covid-19 outbreak on overall revenue, market segments as well as regional market. The report also puts light on detailed impact analysis by taking into consideration all the government policies imposed during the pandemic situation, temporary shutdown of manufacturing units, current state of supply chain and distributors, and its future impacts on the growth of overall market. The market study will assist user to understand the global demand and impose strategic business plans to compete with the peers.

Furthermore, the research report includes the detailed information about major players and provides the data regarding the current market scenario as well as upcoming market opportunities or challenges. Similarly, in segment report covers the types, and applications according to the countries and key regions. The research report consists the various drivers and restraints for Clinical Oncology Next Generation Sequencing (NGS) market along with their effects over the forecast period. Similarly, according to the region Clinical Oncology Next Generation Sequencing (NGS) market research report includes the study of opportunities available in the market situation.

The Clinical Oncology Next Generation Sequencing (NGS) market research report provides the in-depth data analysis by using the various graphs, figures, charts, and tables. Furthermore, the report provides the different business challenges which are impacting market growth in all direction.

Major Key Players for Global Clinical Oncology Next Generation Sequencing (NGS) Market:
The Clinical Oncology Next Generation Sequencing (NGS) market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. Agilent Technologies, Inc., Caris Life Sciences, F. Hoffmann-La Roche Ltd, FOUNDATION MEDICINE, INC., Illumina, Inc., Myriad Genetics, Inc., Oxford Nanopore Technologies, Paradigm Diagnostics, Inc., QIAGEN, Thermo Fisher Scientific Inc.

Clinical Oncology Next Generation Sequencing (NGS) Market Segmentation Analysis:
By Technology
Whole Exome Sequencing
Whole Genome Sequencing and Targeted Sequencing & Resequencing
Workflow
NGS Data Analysis
NGS Pre-Sequencing and NGS Sequencing
Application
Companion Diagnostics
Screening and Other Applications
End User
Hospitals & Clinics and Laboratories


Global Clinical Oncology Next Generation Sequencing (NGS) Market Segmentation by Regions:
In regional analysis, Clinical Oncology Next Generation Sequencing (NGS) market research report provides the detailed analysis from various regions and also contains the detailed analysis of country. Along with market revenue, market value report also offers the forecast analysis for the following countries and regions. Global Clinical Oncology Next Generation Sequencing (NGS) market report covers the various geographical regions such as North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa. Also, various countries included are Canada, U.K., France, the U.S., Japan, China, India, and Germany and so on.

North America Region for Clinical Oncology Next Generation Sequencing (NGS) Market: Value and Forecast
  • U.S.
  • Canada
 Europe Region for Clinical Oncology Next Generation Sequencing (NGS) Market: Value and Forecast
  • UK
  • Germany
  • France
  • Rest of the Europe
 Asia Pacific Region for Clinical Oncology Next Generation Sequencing (NGS) Market: Value and Forecast
  • China
  • Japan
  • India
  • Rest of the Asia Pacific
 Latin America Region for Clinical Oncology Next Generation Sequencing (NGS) Market: Value and Forecast
  • Mexico
  • Brazil
  • Rest of the Latin America
 Middle East and Africa for Clinical Oncology Next Generation Sequencing (NGS) Market: Value and Forecast
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa


Important Points Covered by Report:
  • To analyze the value of the Clinical Oncology Next Generation Sequencing (NGS) market, according to the key region.
  • To study the Clinical Oncology Next Generation Sequencing (NGS) market current trends, prospects and also their participation in the entire sector.
  • Report consists the in-depth information related to the region/countries, major key players, current trends and their analysis, product type, applications, and other background information
  • Report provides the detailed information about drivers, restraints and future scope of Clinical Oncology Next Generation Sequencing (NGS) market.
  • Report covers the information about historic data analysis as well as forecast period analysis.

Global Clinical Oncology Next Generation Sequencing (NGS) research report consist the information about overall sales and revenue during the historic and forecasted period of 2018 to 2028. Additionally, this report covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.

Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Clinical Oncology Next Generation Sequencing (NGS) market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Clinical Oncology Next Generation Sequencing (NGS) market for numerous purposes such as:

    1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Clinical Oncology Next Generation Sequencing (NGS) market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Clinical Oncology Next Generation Sequencing (NGS) market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Clinical Oncology Next Generation Sequencing (NGS) market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Manufacturers and Segments

  • Agilent Technologies, Inc.
  • Caris Life Sciences
  • F. Hoffmann-La Roche Ltd
  • FOUNDATION MEDICINE, INC.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • Oxford Nanopore Technologies
  • Paradigm Diagnostics, Inc.
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Whole Exome Sequencing
  • Whole Genome Sequencing and Targeted Sequencing & Resequencing
  • Hospitals & Clinics and Laboratories

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Clinical Oncology Next Generation Sequencing (NGS) Market Snapshot
          2.1.1. Global Clinical Oncology Next Generation Sequencing (NGS) Market By Technology,2019
               2.1.1.1.Whole Exome Sequencing
               2.1.1.2.Whole Genome Sequencing and Targeted Sequencing & Resequencing
          2.1.2. Global Clinical Oncology Next Generation Sequencing (NGS) Market By End User,2019
               2.1.2.1.Hospitals & Clinics and Laboratories
          2.1.3. Global Clinical Oncology Next Generation Sequencing (NGS) Market By End-use,2019
          2.1.4. Global Clinical Oncology Next Generation Sequencing (NGS) Market By Geography,2019

3. Global Clinical Oncology Next Generation Sequencing (NGS) Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By Technology, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Technology, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Technology, 2020
     4.2. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By Technology, 2018 – 2028

5. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By End User, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By End User, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By End User, 2020
     5.2. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By End User, 2018 – 2028

6. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By End-use, 2018 – 2028

7. Global Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Clinical Oncology Next Generation Sequencing (NGS) Market Analysis, 2018 – 2028 
          7.2.1. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By Technology, 2018 – 2028
          7.2.3. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By End User, 2018 – 2028
          7.2.4. North America Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Analysis, 2018 – 2028 
          7.3.1.  Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By Technology, 2018 – 2028
          7.3.3. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By End User, 2018 – 2028
          7.3.4. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By Technology, 2018 – 2028
          7.4.3. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By End User, 2018 – 2028
          7.4.4. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By Technology, 2018 – 2028
          7.5.3. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By End User, 2018 – 2028
          7.5.4. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Clinical Oncology Next Generation Sequencing (NGS) Market Analysis, 2018 – 2028 
          7.6.1.  MEA Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By Technology, 2018 – 2028
          7.6.3. MEA Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By End User, 2018 – 2028
          7.6.4. MEA Clinical Oncology Next Generation Sequencing (NGS) Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Clinical Oncology Next Generation Sequencing (NGS) Providers
        8.4.1 Agilent Technologies, Inc.
                8.4.1.1 Business Description
                8.4.1.2 Agilent Technologies, Inc. Geographic Operations
                8.4.1.3 Agilent Technologies, Inc. Financial Information
                8.4.1.4 Agilent Technologies, Inc. Product Positions/Portfolio
                8.4.1.5 Agilent Technologies, Inc. Key Developments
        8.4.2 Caris Life Sciences
                8.4.2.1 Business Description
                8.4.2.2 Caris Life Sciences Geographic Operations
                8.4.2.3 Caris Life Sciences Financial Information
                8.4.2.4 Caris Life Sciences Product Positions/Portfolio
                8.4.2.5 Caris Life Sciences Key Developments
        8.4.3 F. Hoffmann-La Roche Ltd
                8.4.3.1 Business Description
                8.4.3.2 F. Hoffmann-La Roche Ltd Geographic Operations
                8.4.3.3 F. Hoffmann-La Roche Ltd Financial Information
                8.4.3.4 F. Hoffmann-La Roche Ltd Product Positions/Portfolio
                8.4.3.5 F. Hoffmann-La Roche Ltd Key Developments
        8.4.4 FOUNDATION MEDICINE, INC.
                8.4.4.1 Business Description
                8.4.4.2 FOUNDATION MEDICINE, INC. Geographic Operations
                8.4.4.3 FOUNDATION MEDICINE, INC. Financial Information
                8.4.4.4 FOUNDATION MEDICINE, INC. Product Positions/Portfolio
                8.4.4.5 FOUNDATION MEDICINE, INC. Key Developments
        8.4.5 Illumina, Inc.
                8.4.5.1 Business Description
                8.4.5.2 Illumina, Inc. Geographic Operations
                8.4.5.3 Illumina, Inc. Financial Information
                8.4.5.4 Illumina, Inc. Product Positions/Portfolio
                8.4.5.5 Illumina, Inc. Key Developments
        8.4.6 Myriad Genetics, Inc.
                8.4.6.1 Business Description
                8.4.6.2 Myriad Genetics, Inc. Geographic Operations
                8.4.6.3 Myriad Genetics, Inc. Financial Information
                8.4.6.4 Myriad Genetics, Inc. Product Positions/Portfolio
                8.4.6.5 Myriad Genetics, Inc. Key Developments
        8.4.7 Oxford Nanopore Technologies
                8.4.7.1 Business Description
                8.4.7.2 Oxford Nanopore Technologies Geographic Operations
                8.4.7.3 Oxford Nanopore Technologies Financial Information
                8.4.7.4 Oxford Nanopore Technologies Product Positions/Portfolio
                8.4.7.5 Oxford Nanopore Technologies Key Developments
        8.4.8 Paradigm Diagnostics, Inc.
                8.4.8.1 Business Description
                8.4.8.2 Paradigm Diagnostics, Inc. Geographic Operations
                8.4.8.3 Paradigm Diagnostics, Inc. Financial Information
                8.4.8.4 Paradigm Diagnostics, Inc. Product Positions/Portfolio
                8.4.8.5 Paradigm Diagnostics, Inc. Key Developments
        8.4.9 QIAGEN
                8.4.9.1 Business Description
                8.4.9.2 QIAGEN Geographic Operations
                8.4.9.3 QIAGEN Financial Information
                8.4.9.4 QIAGEN Product Positions/Portfolio
                8.4.9.5 QIAGEN Key Developments
        8.4.10 Thermo Fisher Scientific Inc.
                8.4.10.1 Business Description
                8.4.10.2 Thermo Fisher Scientific Inc. Geographic Operations
                8.4.10.3 Thermo Fisher Scientific Inc. Financial Information
                8.4.10.4 Thermo Fisher Scientific Inc. Product Positions/Portfolio
                8.4.10.5 Thermo Fisher Scientific Inc. Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Clinical Oncology Next Generation Sequencing (NGS) Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Clinical Oncology Next Generation Sequencing (NGS) Market Revenue, By Technology, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Clinical Oncology Next Generation Sequencing (NGS) Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Clinical Oncology Next Generation Sequencing (NGS) Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Revenue, By Technology, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Revenue, By Technology, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Revenue, By Technology, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Clinical Oncology Next Generation Sequencing (NGS) Market Revenue, By Technology, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Clinical Oncology Next Generation Sequencing (NGS) Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Clinical Oncology Next Generation Sequencing (NGS) Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Clinical Oncology Next Generation Sequencing (NGS): Market Segmentation 
FIG. 2 Global Clinical Oncology Next Generation Sequencing (NGS) Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Clinical Oncology Next Generation Sequencing (NGS) Market, By Technology, 2019 (US$ Mn) 
FIG. 5 Global Clinical Oncology Next Generation Sequencing (NGS) Market, By End User, 2019 (US$ Mn) 
FIG. 6 Global Clinical Oncology Next Generation Sequencing (NGS) Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Clinical Oncology Next Generation Sequencing (NGS) Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Clinical Oncology Next Generation Sequencing (NGS) Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Clinical Oncology Next Generation Sequencing (NGS) Providers, 2019
FIG. 11 Global Clinical Oncology Next Generation Sequencing (NGS) Market Revenue Contribution, By Technology, 2019 & 2028 (Value %) 
FIG. 12 Global Clinical Oncology Next Generation Sequencing (NGS) Market Revenue Contribution, By End User, 2019 & 2028 (Value %) 
FIG. 13 Global Clinical Oncology Next Generation Sequencing (NGS) Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Clinical Oncology Next Generation Sequencing (NGS) Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Clinical Oncology Next Generation Sequencing (NGS) Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Clinical Oncology Next Generation Sequencing (NGS) market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Clinical Oncology Next Generation Sequencing (NGS) Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Clinical Oncology Next Generation Sequencing (NGS) Market Value, By Segment1, 2018 – 2028
TABLE  North America Clinical Oncology Next Generation Sequencing (NGS) Market Value, By Segment2, 2018 – 2028
TABLE  North America Clinical Oncology Next Generation Sequencing (NGS) Market Value, By Country, 2018 – 2028
TABLE  Europe Clinical Oncology Next Generation Sequencing (NGS) Market Value, By Segment1, 2018 – 2028
TABLE  Europe Clinical Oncology Next Generation Sequencing (NGS) Market Value, By Segment2, 2018 – 2028
TABLE  Europe Clinical Oncology Next Generation Sequencing (NGS) Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Value, By Country, 2018 – 2028
TABLE  Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Value, By Country, 2018 – 2028
TABLE  MEA Clinical Oncology Next Generation Sequencing (NGS) Market Value, By Segment1, 2018 – 2028
TABLE  MEA Clinical Oncology Next Generation Sequencing (NGS) Market Value, By Segment2, 2018 – 2028
TABLE  MEA Clinical Oncology Next Generation Sequencing (NGS) Market Value, By Country, 2018 – 2028
TABLE  Agilent Technologies, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Caris Life Sciences: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  F. Hoffmann-La Roche Ltd: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  FOUNDATION MEDICINE, INC.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Illumina, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Myriad Genetics, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Oxford Nanopore Technologies: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Paradigm Diagnostics, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  QIAGEN: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Thermo Fisher Scientific Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Clinical Oncology Next Generation Sequencing (NGS) Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Clinical Oncology Next Generation Sequencing (NGS) Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Clinical Oncology Next Generation Sequencing (NGS) Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Clinical Oncology Next Generation Sequencing (NGS) Market, By Geography, 2019 (US$ Mn)
FIG.  Global Clinical Oncology Next Generation Sequencing (NGS) Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Clinical Oncology Next Generation Sequencing (NGS) Providers, 2016
FIG.  Global Clinical Oncology Next Generation Sequencing (NGS) Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Whole Genome Sequencing and Targeted Sequencing & Resequencing Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Clinical Oncology Next Generation Sequencing (NGS) Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Clinical Oncology Next Generation Sequencing (NGS) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Clinical Oncology Next Generation Sequencing (NGS) Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Clinical Oncology Next Generation Sequencing (NGS) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Clinical Oncology Next Generation Sequencing (NGS) Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Clinical Oncology Next Generation Sequencing (NGS) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Clinical Oncology Next Generation Sequencing (NGS) Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Clinical Oncology Next Generation Sequencing (NGS) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Clinical Oncology Next Generation Sequencing (NGS) Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Clinical Oncology Next Generation Sequencing (NGS) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Clinical Oncology Next Generation Sequencing (NGS) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Clinical Oncology Next Generation Sequencing (NGS) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Clinical Oncology Next Generation Sequencing (NGS) Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Clinical Oncology Next Generation Sequencing (NGS) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Clinical Oncology Next Generation Sequencing (NGS) Market Value, 2018 – 2028, (US$ Mn)